Movement Alert｜Alnylam Pharmaceuticals Intraday Rise 5.23%, rebound emerges as Amvuttra policy concerns ease after recent selloff

Market Focus11-04 22:46

On November 4, Alnylam Pharmaceuticals rose 5.23% in Regular Trading, trading at $164.29 per share, with turnover of $56.2755 million.

The move followed a rebound after recent pressure tied to uncertainty around potential 340B reimbursement changes affecting Amvuttra, while some views in the market continued to characterize the company’s underlying fundamentals as relatively solid despite conservative third-quarter revenue expectations.

Recent updates indicated Alnylam reported third-quarter revenue of $1.46 billion, above the $1.43 billion consensus, while maintaining expected total net product revenue of $4.70 billion to $5.10 billion for the year. Even so, investors had focused on expectations that TTR revenue would trend toward the low end of guidance and on the risk that proposed 2027 340B reimbursement changes could weigh on hospital-channel Amvuttra usage. More recent trading commentary suggested those policy worries had partially eased after earlier declines, helping support a recovery in the shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment